Wyeth factor resource program

ReFacto has been approved by the FDA for control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A. ReFacto is administered through injection. Benefix Patient Assistance Program, a patient assistance program provided by Wyeth Pharmaceuticals, offers Benefixand ReFacto at no cost for up to 90 days to those who are eligible for the program.

Eligibility is based off of the following requirements:. Fill out the program enrollment form located to your right. ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A.

The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto. Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Catalyst can take those proteases and make them work more effectively so the targets can be changed and new diseases could be targeted with Alterases. Collaborations such as this demonstrate the high value of our discovery and protein-engineering capabilities.

Catalyst's latest collaborations are part of a larger partnering strategy that includes a partnership with Wyeth's pharmaceutical division, formed in , for its Alterase therapeutics platform. These lucrative deals, all flush with cash, means Catalyst, a private company with 50 employees, may not have to raise venture capital funding again in the future. While the deals are enormous for us, they are in the early stages of development and we can't say at this point, the impact these collaborations will have on Big Pharma.

Dec 13, Nov 01, Meet the microrobots primed to take down cancer Meet the microrobots primed to take down cancer. Nov 04, Genetic variation in metabolic genes affects drug responses Genetic variation in metabolic genes affects drug responses.

Nautilus Biotech will discover novel recombinant Factor IX proteins and MediVas will discover biopharmaceuticals that extend the duration of action of current treatments. Wyeth Pharmaceuticals signed two separate agreements to improve its hemophilia program with MediVas and Nautilus Biotech.

The research collaboration with MediVas was initiated to discover, develop, manufacture, and commercialize biopharmaceuticals that extend the duration of action of recombinant factor treatments for hemophilia. MediVas will employ a unique polymer-based drug delivery system to develop advanced delivery methods. The company will work to create a longer half-life for these proteins. MediVas will receive milestone and royalty payments based on net sales of products.